<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Middle East J Dig Dis</journal-id><journal-id journal-id-type="iso-abbrev">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">Middle East J Dig Dis</journal-id><journal-id journal-id-type="publisher-id">MEJDD</journal-id><journal-title-group><journal-title>Middle East Journal of Digestive Diseases</journal-title></journal-title-group><issn pub-type="ppub">2008-5230</issn><issn pub-type="epub">2008-5249</issn><issn-l>2008-5230</issn-l><publisher><publisher-name>Iranian Association of Gastroerterology and Hepatology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27698972</article-id><article-id pub-id-type="pmc">5045675</article-id><article-id pub-id-type="doi">10.15171/mejdd.2016.24</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>A Comparison between Hybrid and Concomitant Regimens for <italic>Helicobacter Pylori </italic> Eradication: A Randomized Clinical Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Alhooei</surname><given-names>Saman</given-names></name><xref ref-type="aff" rid="A01">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Tirgar Fakheri</surname><given-names>Hafez</given-names></name><xref ref-type="aff" rid="A02">
<sup>2</sup>
</xref><xref rid="COR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Hosseini</surname><given-names>Vahid</given-names></name><xref ref-type="aff" rid="A03">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Maleki</surname><given-names>Iradj</given-names></name><xref ref-type="aff" rid="A04">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Taghvaei</surname><given-names>Tarang</given-names></name><xref ref-type="aff" rid="A05">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Valizadeh</surname><given-names>Seyed Mohammad</given-names></name><xref ref-type="aff" rid="A06">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Bari</surname><given-names>Zohreh</given-names></name><xref ref-type="aff" rid="A07">
<sup>7</sup>
</xref></contrib></contrib-group><aff id="A01"><sup>1</sup> Assistant Professor, Department of Gastroenterology, Golestan University of Medical Sciences, Gorgan, Iran
</aff><aff id="A02"><sup>2</sup> Professor, Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
</aff><aff id="A03"><sup>3</sup> Associate Professor, Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
</aff><aff id="A04"><sup>4</sup> Associate Professor, Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
</aff><aff id="A05"><sup>5</sup> Associate Professor, Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
</aff><aff id="A06"><sup>6</sup> Assistant Professor, Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
</aff><aff id="A07"><sup>7</sup> Fellow of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran
</aff><author-notes><corresp id="COR1"><label>*</label><bold> Corresponding Author:</bold> Hafez Tirgar Fakheri , MD Department of Gastroenterology, Gut and Liver Research Center, Mazandaran University of Medical Sciences, Sari, Iran Tel: + 98 11 33377176 Fax: + 98 11 33363754 <email>hafezfakheri@gmail.com</email></corresp></author-notes><pub-date pub-type="ppub"><month>7</month><year>2016</year></pub-date><volume>8</volume><issue>3</issue><fpage>219</fpage><lpage>225</lpage><history><date date-type="received"><day>30</day><month>1</month><year>2016</year></date><date date-type="accepted"><day>18</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Middle East Journal of Digestive Diseases</copyright-statement><copyright-year>2016</copyright-year><license><license-p>
This work is published by Middle East Journal of Digestive Diseases as an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link>). Non-commercial uses of the work are permitted, provided the original work is properly cited.
</license-p></license></permissions><self-uri xlink:href="http://www.mejdd.org">http://www.mejdd.org</self-uri><abstract><p>
BACKGROUND
</p><p>
<italic>Helicobacter pylori (H. pylori)</italic> is one of the most common bacterial infections worldwide. We designed a study to compare the efficacy of 14-day hybrid regimen with 10-day concomitant therapy for <italic>H. pylori</italic> eradication in Iran.
</p><p>
METHODS
</p><p>
252 patients with na&#x000ef;ve <italic>H. pylori</italic> infection were randomly divided to receive either hybrid regimen (pantoprazole 40 mg, and amoxicillin 1 gr twice daily for 14 days, accompanied by clarithromycin 500 mg, and metronidazole 500 mg, twice daily just during the last 7 days) or concomitant regimen (pantoprazole 40 mg, amoxicillin 1 gr, clarithromycin 500 mg, and metronidazole 500 mg, all twice daily for 10 days). 8 weeks after therapy, <sup>14</sup>C- urease breath test was performed to confirm eradication.
</p><p>
RESULTS
</p><p>
According to intention to treat analysis, the eradication rates were 87.3% (95% CI: 81.4&#x02013;93.1) and 80.9% (95% CI: 74-87.8) in hybrid and concomitant groups, respectively (<italic>p</italic>=0.38). Per-protocol eradication rates were 89.3% (95% CI: 83.8-94.7) and 83.1% (95% CI: 76.3-89.8), respectively (<italic>p</italic>=0.19). The rates of severe side effects were not statistically different between the two groups (4% vs. 8.7%).
</p><p>
CONCLUSION
</p><p>
14-day hybrid therapy can be considered as a nearly acceptable regimen with few severe side effects in Iran. However, it seems that the efficacy of this therapy is decreasing as the resistance rates to antibiotics are increasing. We suggest further studies to assess the efficacy of a more prolonged concomitant therapy for <italic>H. pylori</italic> eradication in Iran.
</p></abstract><counts><fig-count count="1"/><table-count count="2"/><ref-count count="27"/><page-count count="7"/></counts></article-meta><notes><p>Please cite this paper as:</p><p>Alhooei S, Tirgar Fakheri H, Hosseini V, Maleki I, Taghvaei T, Valizadeh SM, Bari Z. A Comparison between Hybrid and Concomitant Regimens for Helicobacter Pylori Eradication: A Randomized Clinical Trial. Middle East J Dig Dis 2016:219-225. DOI: 10.15171/mejdd.2016.24</p></notes></front><body><sec sec-type="introduction" id="s1"><title>INTRODUCTION</title><p>
<italic>Helicobacter pylori (H. pylori)</italic> is one of the most common bacterial infections worldwide, affecting almost half of the world&#x02019;s population.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref></sup> The prevalence of <italic>H. pylori</italic> infection is estimated to be about 70% in the developing countries and about 30-40% in developed countries.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> The infection is associated with peptic ulcer disease, gastric adenocarcinoma, and lymphoma.<sup><xref rid="R2" ref-type="bibr">2</xref></sup>
</p><p>
Since 1982, many investigations have been performed to introduce a regimen with ideal <italic>H. pylori</italic> eradication rate. Clarithromycin-containing triple therapy had been the gold standard <italic>H. pylori</italic> eradication regimen during the previous years. But the increasing resistance to antibiotics, especially to clarithromycin, has lowered the efficacy of the mentioned therapy to less than 80% in many countries.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Therefore, many investigators have attempted to introduce regimens with higher efficacy for <italic>H. pylori</italic> eradication.
</p><p>
Hybrid regimen is a novel <italic>H. pylori</italic> eradication strategy consisted of a proton pump inhibitor (PPI) plus amoxicillin during the first half of therapy, followed by a concomitant administration of a PPI plus amoxicillin, clarithromycin, and metronidazole or tinidazole. The regimen can be given in 10- or 14-day protocols.<sup><xref rid="R5" ref-type="bibr">5</xref></sup> This strategy has shown ideal eradication rates in recent studies.<sup><xref rid="R6" ref-type="bibr">6</xref>-<xref rid="R9" ref-type="bibr">9</xref></sup>
</p><p>
Concomitant therapy is another novel regimen consisted of concomitant administration of a PPI plus amoxicillin, clarithromycin, and metronidazole for 10 to 14 days. Several studies have shown more than 90% per-protocol <italic>H. pylori</italic> eradication rates by concomitant therapy.<sup><xref rid="R10" ref-type="bibr">10</xref>-<xref rid="R12" ref-type="bibr">12</xref></sup>
</p><p>
Studies comparing concomitant regimen with hybrid therapy mostly have achieved acceptable <italic>H. pylori</italic> eradication rates by both regimens. These studies have mostly compared regimens with the same duration of therapy. However, in the concomitant therapy, a higher number of tablets are administered when compared with hybrid therapy with the same duration of treatment. This can lead to more frequent adverse effects by the concomitant therapy and a higher cost.
</p><p>
Up to now, no study has evaluated the efficacy of concomitant regimen for <italic>H. pylori</italic> eradication in Iran. Iran is a country with high clarithromycin resistance rate. Studies performed in countries with the same pattern of claritromycin resistance have shown acceptable <italic>H. pylori</italic> eradication rates by both 10-day and 14-day concomitant regimens.<sup><xref rid="R13" ref-type="bibr">13</xref>-<xref rid="R15" ref-type="bibr">15</xref></sup> Furthermore, treatment duration of at least 7 days is recommended for the success of concomitant therapy.<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> Therefore, we designed a study to compare the efficacy of 10-day concomitant therapy with 14-day hybrid regimen for <italic>H. pylori</italic> eradication in Iran. Although these two regimens have different durations, they have almost the same number of tablets (120 vs. 126, respectively).
</p></sec><sec sec-type="materials and methods" id="s2"><title>MATERIALS AND METHODS</title><p>
252 patients with peptic ulcer disease or erosive gastro/duodenopathy entered the study. They all had na&#x000ef;ve <italic>H. pylori</italic> infection, confirmed by antral biopsy (Giemsa staining) and rapid urease test. They were randomly divided into 2 groups to receive either hybrid regimen (pantoprazole 40 mg and amoxicillin 1 gr twice daily for 14 days, accompanied by clarithromycin 500 mg and metronidazole 500 mg twice daily just during the last 7 days) or concomitant regimen (pantoprazole 40 mg, amoxicillin 1 gr, clarithromycin 500 mg, and metronidazole 500 mg, all twice daily for 10 days).
</p><p> The protocol was approved by the Ethics Committee of Mazandaran University of Medical Sciences and also, written informed consents were obtained from all patients.</p><p> The patients were advised to take all the prescribed drugs and were visited at the end of treatment to evaluate their compliance to treatment and side effects of therapy. They were also advised to call the physician in case of any severe adverse reaction.</p><p> Side effects of therapy were considered severe, if they abandoned daily activities, moderate if they partially interfered with daily activities, and mild if they were easily tolerable and did not interfere with daily activities.</p><p> Compliance to treatment was considered excellent if the patient took more than 90% of the medications, moderate if he/she took 70-90% of the prescribed drugs, and poor if the patient took less than 70% of medications.</p><p>
Eight weeks after therapy, <sup>14</sup>C- urease breath test (Heliprobe Breath Card and Analyser, Kibion AB, Uppsala, Sweden) was performed to confirm <italic>H. pylori</italic> eradication.
</p><sec id="s2-1"><title>Statistical analysis:</title><p>
In Iran, <italic>H. pylori</italic> eradication rates achieved by 14-day hybrid regimen have been about 92%. On the other hand, no study has evaluated the effects of concomitant therapy on <italic>H. pylori</italic> eradication in Iran. In other countries, the eradication rates achieved by 14-day concomitant regimen have been about 86%. Therefore, we assumed to have about 9% difference between the 14-day hybrid and 10-day concomitant regimens in their ability to eradicate <italic>H. pylori</italic>.
</p><p> Considering &#x003b1;=0.05% and &#x003b2;=0.2% and the equation the number of patients in each arm was calculated to be 96. But we assumed about 20% withdrawal rate, therefore, we included at least 120 patients in each arm.</p><p>
<disp-formula id="m1"><mml:math id="n1"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mover accent="true"><mml:mover accent="true"><mml:mn>2</mml:mn><mml:mo>&#x000af;</mml:mo></mml:mover><mml:mo>&#x002d9;</mml:mo></mml:mover></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mi>&#x003b2;</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>&#x02212;</mml:mo><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>&#x000af;</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>&#x02212;</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula>
</p><p> Eradication rate was evaluated according to intention to treat (ITT) and per-protocol (PP) analyses. In order to calculate ITT eradication rate, all patients who entered the study were evaluated. In order to calculate PP eradication rate, only patients who completed the entire protocol with more than 90% compliance to therapy entered the analysis. Data were analyzed using IBM SPSS software for windows (version 16; SPSS Inc., Chicago, IL, USA) and Pearson chi-square test, t test, and logistic regression analysis were used as appropriate. P values&#x0003c;0.05 were considered as statistically significant. The statistician was blind to the assignment of patients.</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><p>
252 patients entered the study. 126 patients were assigned to each group. The mean ages of the patients were 45.3&#x000b1;12.9 years and 42.9&#x000b1;12.3 years in hybrid and concomitant groups, respectively (<italic>p</italic>=0.12). Other demographic characteristics were not statistically different between the two groups (<xref ref-type="table" rid="T1">table 1</xref>).
</p><table-wrap id="T1" orientation="portrait" position="float"><label>
Table 1
</label><caption><title> Demographic, clinical characteristics, and endoscopic findings of the patients</title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Variable</bold>
</td><td rowspan="1" colspan="1">
<bold>14-day Hybrid</bold>
</td><td rowspan="1" colspan="1">
<bold>10-day Concomitant</bold>
</td><td rowspan="1" colspan="1">
<bold>p value</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Male/ Female %</td><td rowspan="1" colspan="1">35 / 65</td><td rowspan="1" colspan="1">39 / 61</td><td rowspan="1" colspan="1">0.74</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Age (mean&#x000b1;SD) (years)</td><td rowspan="1" colspan="1">45.3 &#x000b1; 12.9</td><td rowspan="1" colspan="1">49.2 &#x000b1; 12.3</td><td rowspan="1" colspan="1">0.12</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">History of GIB* (%)</td><td rowspan="1" colspan="1">6 (4.8)</td><td rowspan="1" colspan="1">10 (7.9)</td><td rowspan="1" colspan="1">0.43</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">History of NSAIDs use** (%)</td><td rowspan="1" colspan="1">14 (11.1)</td><td rowspan="1" colspan="1">15 (11.9)</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Smokers (%)</td><td rowspan="1" colspan="1">18 (14.3)</td><td rowspan="1" colspan="1">21 (16.7)</td><td rowspan="1" colspan="1">0.72</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
Type of ulcer<break/><break/> - Duodenal ulcer<break/><break/> - Gastric ulcer<break/><break/> - Duodenal erosion<break/><break/> - Gastric erosion
</td><td rowspan="1" colspan="1">
<break/><break/>77 (61.1)<break/><break/>21 (16.7)<break/><break/>21 (16.7)<break/><break/>40 (31.7)
</td><td rowspan="1" colspan="1">
<break/><break/>65 (51.6)<break/><break/>30 (23.8)<break/><break/>27 (21.4)<break/><break/>55 (43.7)
</td><td rowspan="1" colspan="1">
<break/><break/>0.16<break/><break/>0.20<break/><break/>0.30<break/><break/>0.08
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Bulbar deformity</td><td rowspan="1" colspan="1">19 (15.1)</td><td rowspan="1" colspan="1">21 (16.7)</td><td rowspan="1" colspan="1">0.86</td></tr></tbody></table><table-wrap-foot><fn><p> *GIB: gastrointestinal bleeding</p><p> **NSAIDs: Non-steroidal anti-inflammatory drugs</p></fn></table-wrap-foot></table-wrap><p> 245 patients completed the study. Three patients in hybrid group and four patients in concomitant group did not perform urea breath test. They had also interrupted therapy because of severe adverse effects.</p><p>
Compliance to treatment was excellent in 122 patients (96.8%) of hybrid therapy group, while one patient (0.8%) had moderate, and three patients (2.4%) had poor compliance to therapy. In concomitant group, compliance to treatment was excellent in 119 patients (94.4%), moderate in three patients (2.4%), and poor in four patients (3.2%). The rates of compliance to treatment did not show significant difference between the two groups (<italic>p</italic> =0.55)
</p><p>
43 patients (34.1%) complained of side effects of therapy in hybrid group, but the adverse effects were severe only in five patients (4%). In concomitant group, 56 patients (44.4%) reported side effects, which were severe in 11 patients (8.7%). However, the rates of total side effects, as well as the rates of severe side effects were not statistically different between the two groups (<italic>p</italic> =0.12 and <italic>p</italic> =0.25, respectively)(<xref ref-type="table" rid="T2">table 2</xref>).
</p><table-wrap id="T2" orientation="portrait" position="float"><label>
Table 2
</label><caption><title>Adverse effects reported by the patients during treatment </title></caption><table frame="hsides" rules="none"><tbody><tr style="border-width: 1px 0px 1pt 0px ; border-style:solid none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
<bold>Adverse effect</bold>
</td><td rowspan="1" colspan="1">
<bold>14-day Hybrid</bold>
</td><td rowspan="1" colspan="1">
<bold>10-day Concomitant</bold>
</td><td rowspan="1" colspan="1">
<bold>p value</bold>
</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Epigastric pain</td><td rowspan="1" colspan="1">5 (4)</td><td rowspan="1" colspan="1">7 (5.6)</td><td rowspan="1" colspan="1">0.76</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Sleepiness </td><td rowspan="1" colspan="1">2 (1.6)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.49</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Anxiety </td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Abdominal cramp</td><td rowspan="1" colspan="1">2 (1.6)</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Weakness </td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">6 (4.8)</td><td rowspan="1" colspan="1">0.12</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Nausea &#x00026; vomiting</td><td rowspan="1" colspan="1">10 (7.9)</td><td rowspan="1" colspan="1">11 (8.7)</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Metallic taste </td><td rowspan="1" colspan="1">26 (20.6)</td><td rowspan="1" colspan="1">28 (22.2)</td><td rowspan="1" colspan="1">0.87</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Dizziness</td><td rowspan="1" colspan="1">6 (4.8)</td><td rowspan="1" colspan="1">6 (4.8)</td><td rowspan="1" colspan="1">1.00</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Constipation</td><td rowspan="1" colspan="1">2 (1.6)</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Dysuria</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Blurred vision</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Rash</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Water brash</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">3 (2.4)</td><td rowspan="1" colspan="1">0.24</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Pruritus</td><td rowspan="1" colspan="1">2 (1.6)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.49</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Headache</td><td rowspan="1" colspan="1">3 (2.4)</td><td rowspan="1" colspan="1">6 (4.8)</td><td rowspan="1" colspan="1">0.50</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Tremor </td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Glossitis </td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">1.00</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Stomatitis </td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">2 (1.6)</td><td rowspan="1" colspan="1">0.47</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">3 (2.4)</td><td rowspan="1" colspan="1">5 (4)</td><td rowspan="1" colspan="1">0.74</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Bloating</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">1.00</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Fever</td><td rowspan="1" colspan="1">1 (0.8)</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0.99</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">Anorexia</td><td rowspan="1" colspan="1">2 (1.6)</td><td rowspan="1" colspan="1">7 (5.6)</td><td rowspan="1" colspan="1">0.17</td></tr><tr style="border-width: 0px 0px 1pt 0px ; border-style:none none solid none;border-color:#00adee"><td rowspan="1" colspan="1">
Severity of side effects N (%)<break/><break/> - Mild<break/><break/> - Moderate<break/><break/> - Severe
</td><td rowspan="1" colspan="1">
<break/><break/>24 (0.19)<break/><break/>14 (11.1)<break/><break/>5 (4)
</td><td rowspan="1" colspan="1">
<break/><break/>27 (21.4)<break/><break/>18 (14.3)<break/><break/>11 (8.7)
</td><td rowspan="1" colspan="1">
<break/><break/>0.25
</td></tr></tbody></table><table-wrap-foot><fn><p>*GIB: gastrointestinal bleeding</p><p>
**NSAIDs: Non-steroidal anti-inflammatory drugs
</p></fn></table-wrap-foot></table-wrap><p>
According to ITT analysis, the eradication rates were 87.3% (95% confidence interval (CI) 81.4-93.1) and 80.9% (95% CI: 74-87.8) in hybrid and concomitant groups, respectively (<italic>p</italic> =0.38). PP eradication rates were 89.3% (95% CI: 83.8-94.7) and 83.1% (95% CI: 76.3-89.8), respectively (<italic>p</italic> = 0.19, <xref ref-type="fig" rid="F1">figure 1</xref>).
</p><fig id="F1" orientation="portrait" position="float"><label>
Fig 1
</label><graphic xlink:href="mejdd-8-219-g001"/><statement><p> Method of follow up and treatment efficacy</p></statement></fig></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>
According to the results of the present study, 14-day hybrid therapy could achieve 87.3% and 89.3% <italic>H. pylori</italic> eradication rates according to ITT and PP analyses, respectively. On the other hand, the eradication rates achieved by concomitant regimen were 80.9% and 83.1%, respectively.
</p><p>
If we consider <italic>H. pylori</italic> infection as an infectious disease, an ideal regimen would be the one that can eradicate <italic>H. pylori</italic> in more than 95% of cases, with less than 5% severe adverse effects.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> According to Graham&#x02019;s classification, the efficacy of <italic>H. pylori</italic> eradication regimens are considered as A: excellent (&#x0003e;95% PP eradication rate), B: good (90-95%), C: fair (85-89%), D: poor (81-84%), and F: unacceptable (&#x02264;80% PP eradication rate).<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Therefore, in our study, hybrid and concomitant regimens are classified as fair (C) and poor (D) regimens, respectively. However, the eradication rate achieved by hybrid therapy was nearly good (89.3%).
</p><p> The rate of side effects is also an important issue. In our study, the incidence rates of adverse effects of therapy were 34.1% and 44.4% in hybrid and concomitant groups, respectively. However, they were mostly mild and the rates of severe adverse effects were 4% and 8.7%, respectively. Accordingly, 14-day hybrid regimen can be considered as a nearly good regimen with few severe side effects.</p><p>
In Iran, only few studies have evaluated the effects of hybrid therapy on <italic>H. pylori</italic> eradication. In 2013, Sardarian and colleagues compared the effects of 14-day hybrid regimen vs. 10-day sequential therapy on 420 patients with peptic ulcer disease. The eradication rates achieved by hybrid therapy were 89.5% and 92.9% according to ITT and PP analyses, respectively.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Furthermore, in 2015, Metanat and co-workers compared 10-day vs. 14-day hybrid therapy on 270 patients with peptic ulcer disease in Iran. The ITT eradication rates were 77.6% and 86% for 10-day and 14-day regimens, respectively. Also, PP eradication rates were 83.8% and 92.8%, respectively. This study, highlighted the ideal efficacy of 14-day hybrid regimen for <italic>H. pylori</italic> eradication in Iran.<sup><xref rid="R20" ref-type="bibr">20</xref></sup>
</p><p>
Comparing the results of our study with the two previous studies performed in Iran, the lower rates of <italic>H. pylori</italic> eradication in our study might have been due to the increasing antibiotic resistance. In Iran, during the previous years, the rate of <italic>H. pylori</italic> resistance to clarithromycin has increased from 1.4% in 1997 to 14.3% in 2012. Also, the rate of resistance to metronidazole has increased from 33% to 76%.<sup><xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup>
</p><p>
Considering concomitant therapy, no study had previously evaluated concomitant therapy for <italic>H. pylori</italic> eradication in Iran. Therefore, we cannot compare our results with the same studies in our country.
</p><p>
In other countries, hybrid and concomitant regimens have mostly achieved acceptable <italic>H. pylori</italic> eradication rates. In 2013, Zullo and others compared the effects of 14-day hybrid regimen with 5-day concomitant therapy on patients with non-ulcer dyspepsia in Italy. The ITT eradication rates were 80% and 85.5%, respectively. Also, PP eradication rates were 85.7% and 91.6%, respectively. In the mentioned study, differences in the eradication rates were not statistically significant.<sup><xref rid="R12" ref-type="bibr">12</xref></sup>
</p><p>
In 2014, De Francesco and colleagues compared 14-day hybrid regimen with 14-day and 5-day concomitant therapies in Italy. ITT eradication rates were 82.7%, 86.3%, and 78.1%, respectively. The differences between the eradication rates were not statistically significant between either 14-day hybrid or 14-day concomitant therapies, but the rate achieved by 5-day concomitant regimen was significantly lower than the other two groups.<sup><xref rid="R14" ref-type="bibr">14</xref></sup>
</p><p>
Italy is a country with high resistance rates to antibiotics against <italic>H. pylori</italic>, similar to our country.<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> The two studies performed in Italy demonstrate a tendency toward decrease in <italic>H. pylori</italic> eradication rates by hybrid and concomitant regimens. This is similar to the results of studies performed in Iran.
</p><p>
In 2013, Molina-infante and co-workers compared 14-day hybrid regimen versus 14-day concomitant regimen for <italic>H. pylori</italic> eradication in Spain. The ITT eradication rates were 90% and 91.7%, respectively. Also, PP eradication rates were 92% and 96.1%, respectively. Accordingly, both hybrid and concomitant regimens could achieve ideal eradication rates.<sup><xref rid="R13" ref-type="bibr">13</xref></sup>
</p><p>
In 2015, Molina-infante and colleagues compared the efficacy of optimized (high dose acid suppression) 14-day concomitant therapy with optimized triple therapy in Spain.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> The eradication rates achieved by concomitant therapy were 90.4% and 93.8% according to ITT and PP analyses, respectively.
</p><p>
Although Spain is also a country with high resistance rates to antibiotics against <italic>H. pylori</italic>, the results of the latter two studies performed in Spain showed higher eradication rates compared with our results. These differences might have been due to differences in dual or multi-drug antibiotic resistance or the differences in patient selection criteria.
</p><p>
The results of studies performed in Asia are almost the same as the mentioned studies. In 2015, Heo and others compared 10-day hybrid and 10-day concomitant therapies in Korea. The eradication rates achieved by ITT analysis were 78.8% and 78.6%, respectively. Also, PP eradication rates were 89.6% and 89.8%, respectively. Both regimens had similar and acceptable efficacies, but hybrid regimen was better tolerated and had fewer side effects.<sup><xref rid="R25" ref-type="bibr">25</xref></sup>
</p><p>
In 2012, Gisbert performed a meta-analysis of the studies evaluating the effects of concomitant regimen for <italic>H. pylori</italic> eradication. 19 studies, including 2070 patients were evaluated. The ITT eradication rate was 88%. Furthermore, a tendency toward higher eradication rates with 10-day versus 5-day regimens was observed.<sup><xref rid="R11" ref-type="bibr">11</xref></sup>
</p><p>
Also, in 2014, Lei He and co-workers performed a meta-analysis to compare sequential, concomitant, and hybrid therapies for <italic>H. pylori</italic> eradication. Ten randomized clinical trials consisted of 3501 patients were included. The ITT eradication rates were 86.7% and 86.6% for the concomitant and hybrid regimens, respectively. PP eradication rates were 89.8% and 92.7%, respectively. This meta-analysis showed no significant difference between the two regimens in terms of <italic>H. pylori</italic> eradication rates or adverse effects of therapies.<sup><xref rid="R26" ref-type="bibr">26</xref></sup>
</p><p>
Totally, in countries with high antibiotic resistance rates, quadruple non-bismuth therapy (including concomitant, hybrid, or sequential regimens) is a first line option.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> But the results of our study and the other studies performed in other countries have mostly been borderline (near 90%). It is thought that dual clarithromycin-metronidazole resistance is the weak point in achieving excellent eradication rates by non-bismuth quadruple therapies.
</p><p>
The main limitation of the present study was the unavailability of <italic>H. pylori</italic> culture. However, the latest study performed in our province (Mazandaran) has reported 30% resistance to clarithromycin, 73.4% resistance to metronidazole, and 6.8% to amoxicillin.<sup><xref rid="R27" ref-type="bibr">27</xref></sup>
</p><p>
The strong point of the present study is being the first study evaluating the effects of concomitant regimen on <italic>H. pylori</italic> eradication in Iran.
</p><p>
In conclusion, 14-day hybrid regimen can be considered as a nearly acceptable regimen with few severe side effects in Iran. However, it seems that the efficacy of this therapy is decreasing as the resistance rates to antibiotics are increasing. We suggest further studies to assess the efficacy of a more prolonged concomitant therapy for <italic>H. pylori</italic> eradication in Iran.
</p></sec><sec id="s5"><title>ACKNOWLEDGEMENTS</title><p> The authors acknowledge the &#x0fb01;nancial support of Mazandaran University of Medical Sciences.</p></sec><sec id="s6"><title>CONFLICT OF INTEREST</title><p> The authors declare no conflict of interest related to this work.</p></sec></body><back><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><name><surname>Linz</surname><given-names>B</given-names></name><name><surname>Balloux</surname><given-names>F</given-names></name><name><surname>Moodley</surname><given-names>Y</given-names></name><name><surname>Manica</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Roumagnac</surname><given-names>P</given-names></name><etal/><article-title>An African origin for the intimate association between humans and Helicobacter pylori</article-title><source>Nature</source><year>2007</year><volume>445</volume><fpage>915</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature05562</pub-id><pub-id pub-id-type="pmid">17287725</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><name><surname>Go</surname><given-names>MF</given-names></name><article-title>Review article: natural history and epidemiology of Helicobacter pylori infection</article-title><source>Aliment Pharmacol Ther</source><year>2002</year><volume>16</volume><fpage>3</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2036.2002.0160s1003.x</pub-id><pub-id pub-id-type="pmid">11849122</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><name><surname>Becker</surname><given-names>SI</given-names></name><name><surname>Smalligan</surname><given-names>RD</given-names></name><name><surname>Frame</surname><given-names>JD</given-names></name><name><surname>Kleanthous</surname><given-names>H</given-names></name><name><surname>Tibbitts</surname><given-names>TJ</given-names></name><name><surname>Monath</surname><given-names>TP</given-names></name><etal/><article-title>Risk of Helicobacter pylori infection among long-term residents in developing countries</article-title><source>Am J Trop Med Hyg</source><year>1999</year><volume>60</volume><fpage>267</fpage><lpage>70</lpage><pub-id pub-id-type="pmid">10072149</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><name><surname>Tokunaga</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>A</given-names></name><name><surname>Sugano</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>S</given-names></name><article-title>[The present status and problems of Helicobacter pylori first-line eradication therapy]</article-title><source>Nihon Rinsho</source><year>2009</year><volume>67</volume><fpage>2291</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">19999114</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><name><surname>Hsu</surname><given-names>PI</given-names></name><name><surname>Wu</surname><given-names>DC</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><article-title>Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days</article-title><source>Helicobacter</source><year>2011</year><volume>16</volume><fpage>139</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2011.00828.x</pub-id><pub-id pub-id-type="pmid">21435092</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><name><surname>Kim</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Hyun</surname><given-names>JJ</given-names></name><name><surname>Jung</surname><given-names>SW</given-names></name><name><surname>Koo</surname><given-names>JS</given-names></name><name><surname>Yim</surname><given-names>HJ</given-names></name><etal/><article-title>Comparative study of Helicobacter pylori eradication rates with 5-day quadruple &#x0201c;concomitant&#x0201d; therapy and 7-day standard triple therapy</article-title><source>J Clin Gastroenterol</source><year>2013</year><volume>47</volume><fpage>21</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1097/MCG.0b013e3182548ad4</pub-id><pub-id pub-id-type="pmid">22647826</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><name><surname>Kongchayanun</surname><given-names>C</given-names></name><name><surname>Vilaichone</surname><given-names>RK</given-names></name><name><surname>Pornthisarn</surname><given-names>B</given-names></name><name><surname>Amornsawadwattana</surname><given-names>S</given-names></name><name><surname>Mahachai</surname><given-names>V</given-names></name><article-title>Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand</article-title><source>Helicobacter</source><year>2012</year><volume>17</volume><fpage>282</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2012.00953.x</pub-id><pub-id pub-id-type="pmid">22759328</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><name><surname>O&#x02019;Connor</surname><given-names>A</given-names></name><name><surname>Molina-Infante</surname><given-names>J</given-names></name><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>O&#x02019;Morain</surname><given-names>C</given-names></name><article-title>Treatment of Helicobacter pylori infection 2013</article-title><source>Helicobacter</source><year>2013</year><volume>1</volume><fpage>58</fpage><lpage>65</lpage><pub-id pub-id-type="doi">10.1111/hel.12075</pub-id><pub-id pub-id-type="pmid">24011247</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Liou</surname><given-names>JM</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><article-title>Evidence-based recommendations for successful Helicobacter pylori treatment</article-title><source>Expert Rev Gastroenterol Hepatol</source><year>2014</year><volume>8</volume><fpage>21</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1586/17474124.2014.859522</pub-id><pub-id pub-id-type="pmid">24410470</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Wu</surname><given-names>DC</given-names></name><name><surname>Hsu</surname><given-names>PI</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Opekun</surname><given-names>AR</given-names></name><name><surname>Kuo</surname><given-names>CH</given-names></name><name><surname>Wu</surname><given-names>IC</given-names></name><etal/><article-title>Sequential and concomitant therapy with four drugs is equally effective for eradication of H pylori infection</article-title><source>Clin Gastroenterol Hepatol</source><year>2010</year><volume>8</volume><fpage>36</fpage><lpage>41 e1</lpage><pub-id pub-id-type="doi">10.1016/j.cgh.2009.09.030</pub-id><pub-id pub-id-type="pmid">19804842</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Gisbert</surname><given-names>JP</given-names></name><name><surname>Calvet</surname><given-names>X</given-names></name><article-title>Update on non-bismuth quadruple (concomitant) therapy for eradication of Helicobacter pylori</article-title><source>Clin Exp Gastroenterol</source><year>2012</year><volume>5</volume><fpage>23</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.2147/CEG.S25419</pub-id><pub-id pub-id-type="pmid">22457599</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Scaccianoce</surname><given-names>G</given-names></name><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Ruggiero</surname><given-names>V</given-names></name><name><surname>D&#x02019;Ambrosio</surname><given-names>P</given-names></name><name><surname>Castorani</surname><given-names>L</given-names></name><etal/><article-title>Concomitant, sequential, and hybrid therapy for H pylori eradication: a pilot study</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2013</year><volume>37</volume><fpage>647</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/j.clinre.2013.04.003</pub-id><pub-id pub-id-type="pmid">23747131</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Molina-Infante</surname><given-names>J</given-names></name><name><surname>Romano</surname><given-names>M</given-names></name><name><surname>Fernandez-Bermejo</surname><given-names>M</given-names></name><name><surname>Federico</surname><given-names>A</given-names></name><name><surname>Gravina</surname><given-names>AG</given-names></name><name><surname>Pozzati</surname><given-names>L</given-names></name><etal/><article-title>Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance</article-title><source>Gastroenterology</source><year>2013</year><volume>145</volume><fpage>121</fpage><lpage>8 e1</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2013.03.050</pub-id><pub-id pub-id-type="pmid">23562754</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>De Francesco</surname><given-names>V</given-names></name><name><surname>Hassan</surname><given-names>C</given-names></name><name><surname>Ridola</surname><given-names>L</given-names></name><name><surname>Giorgio</surname><given-names>F</given-names></name><name><surname>Ierardi</surname><given-names>E</given-names></name><name><surname>Zullo</surname><given-names>A</given-names></name><article-title>Sequential, concomitant and hybrid first-line therapies for Helicobacter pylori eradication: a prospective randomized study</article-title><source>J Med Microbiol</source><year>2014</year><volume>63</volume><fpage>748</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1099/jmm.0.072322-0</pub-id><pub-id pub-id-type="pmid">24586031</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Molina-Infante</surname><given-names>J</given-names></name><name><surname>Gisbert</surname><given-names>JP</given-names></name><article-title>Optimizing clarithromycin-containing therapy for Helicobacter pylori in the era of antibiotic resistance</article-title><source>World J Gastroenterol</source><year>2014</year><volume>20</volume><fpage>10338</fpage><lpage>47</lpage><pub-id pub-id-type="doi">10.3748/wjg.v20.i30.10338</pub-id><pub-id pub-id-type="pmid">25132750</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Essa</surname><given-names>AS</given-names></name><name><surname>Kramer</surname><given-names>JR</given-names></name><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Treiber</surname><given-names>G</given-names></name><article-title>Meta-analysis: four-drug, three-antibiotic, non-bismuth-containing &#x0201c;concomitant therapy&#x0201d; versus triple therapy for Helicobacter pylori eradication</article-title><source>Helicobacter</source><year>2009</year><volume>14</volume><fpage>109</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2009.00671.x</pub-id><pub-id pub-id-type="pmid">19298338</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Papastergiou</surname><given-names>V</given-names></name><name><surname>Georgopoulos</surname><given-names>SD</given-names></name><name><surname>Karatapanis</surname><given-names>S</given-names></name><article-title>Treatment of Helicobacter pylori infection: Past, present and future</article-title><source>World J Gastrointest Pathophysiol</source><year>2014</year><volume>5</volume><fpage>392</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.4291/wjgp.v5.i4.392</pub-id><pub-id pub-id-type="pmid">25400982</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Graham</surname><given-names>DY</given-names></name><name><surname>Lu</surname><given-names>H</given-names></name><name><surname>Yamaoka</surname><given-names>Y</given-names></name><article-title>A report card to grade Helicobacter pylori therapy</article-title><source>Helicobacter</source><year>2007</year><volume>12</volume><fpage>275</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2007.00518.x</pub-id><pub-id pub-id-type="pmid">17669098</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Sardarian</surname><given-names>H</given-names></name><name><surname>Fakheri</surname><given-names>H</given-names></name><name><surname>Hosseini</surname><given-names>V</given-names></name><name><surname>Taghvaei</surname><given-names>T</given-names></name><name><surname>Maleki</surname><given-names>I</given-names></name><name><surname>Mokhtare</surname><given-names>M</given-names></name><article-title>Comparison of hybrid and sequential therapies for Helicobacter pylori eradication in Iran: a prospective randomized trial</article-title><source>Helicobacter</source><year>2013</year><volume>18</volume><fpage>129</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/hel.12017</pub-id><pub-id pub-id-type="pmid">23121338</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Metanat</surname><given-names>HA</given-names></name><name><surname>Valizadeh</surname><given-names>SM</given-names></name><name><surname>Fakheri</surname><given-names>H</given-names></name><name><surname>Maleki</surname><given-names>I</given-names></name><name><surname>Taghvaei</surname><given-names>T</given-names></name><name><surname>Hosseini</surname><given-names>V</given-names></name><etal/><article-title>Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial</article-title><source>Helicobacter</source><year>2015</year><volume>20</volume><fpage>299</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1111/hel.12202</pub-id><pub-id pub-id-type="pmid">25752357</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Milani</surname><given-names>M</given-names></name><name><surname>Ghotaslou</surname><given-names>R</given-names></name><name><surname>Akhi</surname><given-names>MT</given-names></name><name><surname>Nahaei</surname><given-names>MR</given-names></name><name><surname>Hasani</surname><given-names>A</given-names></name><name><surname>Somi</surname><given-names>MH</given-names></name><etal/><article-title>The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics</article-title><source>J Infect Chemother</source><year>2012</year><volume>18</volume><fpage>848</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1007/s10156-012-0425-4</pub-id><pub-id pub-id-type="pmid">22581031</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Safaralizadeh</surname><given-names>R</given-names></name><name><surname>Siavoshi</surname><given-names>F</given-names></name><name><surname>Malekzadeh</surname><given-names>R</given-names></name><name><surname>Akbari</surname><given-names>MR</given-names></name><name><surname>Derakhshan</surname><given-names>MH</given-names></name><name><surname>Sohrabi</surname><given-names>MR</given-names></name><etal/><article-title>Antimicrobial effectiveness of furazolidone against metronidazole-resistant strains of Helicobacter pylori</article-title><source>East Mediterr Health J</source><year>2006</year><volume>12</volume><fpage>286</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">17037696</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Saracino</surname><given-names>IM</given-names></name><name><surname>Zullo</surname><given-names>A</given-names></name><name><surname>Holton</surname><given-names>J</given-names></name><name><surname>Castelli</surname><given-names>V</given-names></name><name><surname>Fiorini</surname><given-names>G</given-names></name><name><surname>Zaccaro</surname><given-names>C</given-names></name><etal/><article-title>High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy</article-title><source>J Gastrointestin Liver Dis</source><year>2012</year><volume>21</volume><fpage>363</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">23256118</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Agudo</surname><given-names>S</given-names></name><name><surname>Alarcon</surname><given-names>T</given-names></name><name><surname>Cibrelus</surname><given-names>L</given-names></name><name><surname>Urruzuno</surname><given-names>P</given-names></name><name><surname>Martinez</surname><given-names>MJ</given-names></name><name><surname>Lopez-Brea</surname><given-names>M</given-names></name><article-title>[High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]</article-title><source>Rev EspQuimioter</source><year>2009</year><volume>22</volume><fpage>88</fpage><lpage>92</lpage></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Heo</surname><given-names>J</given-names></name><name><surname>Jeon</surname><given-names>SW</given-names></name><name><surname>Jung</surname><given-names>JT</given-names></name><name><surname>Kwon</surname><given-names>JG</given-names></name><name><surname>Lee</surname><given-names>DW</given-names></name><name><surname>Kim</surname><given-names>HS</given-names></name><etal/><article-title>Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial</article-title><source>J Gastroenterol Hepatol</source><year>2015</year><volume>30</volume><fpage>1361</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1111/jgh.12983</pub-id><pub-id pub-id-type="pmid">25867608</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>He</surname><given-names>L</given-names></name><name><surname>Deng</surname><given-names>T</given-names></name><name><surname>Luo</surname><given-names>H</given-names></name><article-title>Meta-analysis of sequential, concomitant and hybrid therapy for Helicobacter pylori eradication</article-title><source>Intern Med</source><year>2015</year><volume>54</volume><fpage>703</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.2169/internalmedicine.54.3442</pub-id><pub-id pub-id-type="pmid">25832929</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Talebi Bezmin Abadi</surname><given-names>A</given-names></name><name><surname>Mobarez</surname><given-names>AM</given-names></name><name><surname>Taghvaei</surname><given-names>T</given-names></name><name><surname>Wolfram</surname><given-names>L</given-names></name><article-title>Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran</article-title><source>Helicobacter</source><year>2010</year><volume>15</volume><fpage>505</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1523-5378.2010.00795.x</pub-id><pub-id pub-id-type="pmid">21073606</pub-id></element-citation></ref></ref-list></back></article>